Innovative Drug Targeting for Brain Cancer: A Study Overview

Understanding Glioblastoma

A recent study published in *Scientific Reports* has introduced a novel approach to drug targeting for brain cancer, specifically focusing on glioblastoma. This aggressive form of cancer accounts for 12-15% of all intracranial brain tumors and is considered one of the most lethal cancers. Glioblastomas develop from abnormal astrocytes, which are brain cells responsible for nourishing the blood vessels that supply the brain. Despite the use of surgery, chemotherapy, and radiotherapy, the survival rate for glioblastoma patients remains grim, averaging only 12-15 months.

The Challenge of Targeted Drug Delivery

The quest for effective glioblastoma treatments is complicated by the difficulty of delivering drugs to the brain. The presence of interstitial fluid, which occupies the spaces around cells in tissues, is a significant factor in the spread of cancer cells. This fluid, comprising mainly cerebrospinal fluid, accounts for 15-20% of brain volume and circulates at higher pressures in glioblastoma patients, facilitating the spread of tumor cells throughout brain tissue. Current treatment methods involving catheters to deliver drugs can inadvertently enhance the convective flow of interstitial fluid, exacerbating the problem.

Research Findings on Interstitial Fluid and Drug Compounds

Researchers from Virginia Tech investigated the potential to mitigate the spread of cancer cells by addressing the convective properties of interstitial fluid. Their findings, published in *Scientific Reports*, reveal that this fluid promotes the dissemination of cancer cells via a convection-powered mechanism reliant on a molecule known as CXCR4. The team successfully blocked this protein using AMD3100, an FDA-validated compound currently in clinical use.

In their study, the researchers administered AMD3100 at a dosage of 5mg/kg, effectively inhibiting the invasion of glioblastoma cells. They observed that patients who received convection-enhanced drug delivery exhibited elevated levels of CXCR4.

Future Directions and Research Needs

The authors of the study propose that AMD3100 may be particularly advantageous for patients utilizing convection-enhanced delivery methods. However, most of the research was conducted using pre-clinical mouse models, indicating that further extensive studies are needed to establish the compound’s efficacy in human glioblastoma patients.

Reference

Cornelison, R. C., Brennan, C. E., Kingsmore, K. M., & Munson, J. M. (2018). Convective forces increase CXCR4-dependent glioblastoma cell invasion in GL261 murine model. *Scientific Reports*, 8(1), 17057. doi:10.1038/s41598-018-35141-9

Author Information

Written by Vinayak Khattar, Ph.D., M.B.A.